ISL1, INSM1, and SECG all presented with exceedingly high PPVs concerning the distinction between NENs and non-NENs in the clinical setting, irrespective of WHO grade or tumor origin (primary tumor vs. metastasis). This evidence concerns the gene ISL1 and neoplasm.